Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.57 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | QSOX1 | O00391 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3240697 | 0.99 | KMT2A (0.58) | KMT2AKCNQ3KCNQ2MEN1NPC1 | |
| SCHEMBL4083734 | 0.88 | KMT2A (0.56) | KMT2AKCNQ3KCNQ2MEN1NPC1 | |
| Hydrochloric Acid SCHEMBL4085659 | 0.87 | KMT2A (0.55) | KMT2AKCNQ3KCNQ2MEN1NPC1 | |
| SCHEMBL3244037 | 0.85 | KDM4E (0.45) | KMT2AKCNQ3KCNQ2NPC1RAB9A | |
| SCHEMBL4085694 | 0.85 | KCNQ3 (0.57) | KMT2AKCNQ3KCNQ2MEN1NPC1 | |
| SCHEMBL3252070 | 0.85 | ULK1 (0.47) | KCNQ3KCNQ2NPC1RAB9AMAPT | |
| SCHEMBL3248601 | 0.85 | NPC1 (0.64) | KMT2AMEN1NPC1RAB9ATP53 | |
| SCHEMBL3248045 | 0.85 | RORC (0.53) | DGAT1CYP3A4SOAT1 | |
| SCHEMBL3246091 | 0.85 | KCNH2 (0.51) | KMT2AKCNQ3KCNQ2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3252697 | 0.84 | ULK1 (0.46) | KCNQ3KCNQ2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | claimed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | claimed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | claimed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | claimed |
| US-8236793-B2 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NEUROSEARCH A/S (DK) | 2012-08-07 | — | — | US | disclosed |
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | ANIONA APS (DK) | 2010-05-06 | — | — | US | disclosed |
| EP-2172469-A1 | Diazabicyclic aryl derivatives as cholinergic receptor modulators | NeuroSearch A/S (DK) | 2010-04-07 | — | — | EP | disclosed |
| US-7662808-B2 | N-[4-(1,4-Diaza-bicyclo[3.2.2]non-4-yl)-phenyl]-benzamide; disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | ANIONA APS (DK) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113428-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS CHOLINERGIC RECEPTOR MODULATORS | CHRNA6, CHRNA10, CHRNA2 | KMT2A 1679/4885KCNQ3 719/4885KCNQ2 673/4885 |
| US-20080227773-A1 | Diazabicyclic Aryl Derivatives as Cholinergic Receptor Modulators | CHRNA6, CHRNA10, CHRNA2 | KMT2A 1691/4885KCNQ3 724/4885KCNQ2 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.